The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal levels of a protein known as HER2 that is the target of several new therapies.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/oJEcTBL
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» AstraZeneca gets EU backing for targeted breast cancer therapies
https://ift.tt/LBotTrZ
No comments:
Post a Comment